Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. As a PD-1 blocking antibody, Nivolumab is used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
Product Details
| Reactivity | Human |
| Specificity | Detects human PD-1 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Nivolumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB008 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human PD-1 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • Flow Cytometry: 0.25 µg/106 cells |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |